PDSB Earnings Date: Nov 12, 2026 (Estimated) — PDS Biotechnology Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is PDSB's next earnings date?
PDS Biotechnology Corporation (PDSB) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.11.
How did PDSB do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), PDS Biotechnology Corporation posted EPS of -$0.18 versus the -$0.13 estimate, a miss of 38.5%. Revenue was $0. The stock's 1-day post-earnings move was -3.6%.
How much does PDSB stock move after earnings?
PDSB beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.8% (up or down) in the day after earnings.
About PDS Biotechnology Corporation
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.13 | -0.18 | -38.46% | $0 | ❌ Miss | -3.64% | -17.07% | +21.86% |
| 2026-05-13 | Q1 2026 | -0.14 | -0.13 | +7.14% | $0 | ✅ Beat | +20.91% | -9.09% | +1.82% |
| 2026-03-30 | Q4 2025 | -0.20 | -0.14 | +30.00% | $0 | ✅ Beat | -0.91% | +44.14% | +99.48% |
| 2025-11-13 | Q3 2025 | -0.20 | -0.19 | +5.00% | $0 | ✅ Beat | -12.33% | -22.18% | +1.07% |
| 2025-08-13 | Q2 2025 | -0.24 | -0.21 | +12.50% | $0 | ✅ Beat | -5.69% | -4.88% | -4.07% |
| 2025-03-27 | Q4 2024 | -0.28 | -0.21 | +25.00% | $0 | ✅ Beat | +0.81% | -6.85% | +0.81% |
| 2024-11-14 | Q3 2024 | -0.28 | -0.29 | -3.57% | $0 | ❌ Miss | -18.33% | -26.50% | -33.21% |
| 2024-08-13 | Q2 2024 | -0.34 | -0.23 | +32.35% | $0 | ✅ Beat | +0.00% | +15.41% | +1.64% |
Showing last 8 quarters.